Joo‐Yong Hahn - Concepedia

Author

Joo‐Yong Hahn

Samsung Medical Center ORCID

Also Known As

J HAHN, J Hahn, J Y Hahn, J. Hahn, J. Y. Hahn, J.-Y Hahn, J.-Y. Hahn, J.Y Hahn, J.Y. Hahn, Jeong Hoon Yang

580

Publications

14.2K

Citations

H-Index

Concepts

All Affiliations

Samsung Medical Center Sungkyunkwan University Seoul National University Hospital Chonnam National University Hospital Keimyung University

About

Joo‐Yong Hahn is an author at Samsung Medical Center specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	97	5.8K
2	Public Health	24	35	1.9K
3	Health Sciences	6	6	176
4	Engineering	2	2	68
5	Applied Physiology	1	1	47

Joo‐Yong Hahn

205

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Hyeon‐Cheol Gwon, Joo‐Yong Hahn, Kyung Woo Park, Circulation	2011	601
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention Joo‐Yong Hahn, Young Bin Song, Ju Hyeon Oh, JAMA	2019	588
Intravascular Imaging–Guided or Angiography-Guided Complex PCI Joo Myung Lee, Ki Hong Choi, Young Bin Song, New England Journal of Medicine	2023	453
Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation* Tae Gun Shin, Jin‐Ho Choi, Ik Joon Jo, Critical Care Medicine	2010	413
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial Joo‐Yong Hahn, Young Bin Song, Ju Hyeon Oh, The Lancet Percutaneous Coronary InterventionThrombosisCardiovascular DiseaseClinical TrialsAcute Coronary Syndrome	2018	352
Pre-Treatment of Mesenchymal Stem Cells With a Combination of Growth Factors Enhances Gap Junction Formation, Cytoprotective Effect on Cardiomyocytes, and Therapeutic Efficacy for Myocardial Infarction Joo‐Yong Hahn, Hyun-Ju Cho, Hyun‐Jae Kang, Journal of the American College of Cardiology Regenerative MedicineMesenchymal Stem CellsMedicineAdult Stem CellCardiac Progenitor Cells	2008	311
Predictors and Outcomes of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions Joo‐Yong Hahn, Woo Jung Chun, Ji‐Hwan Kim, Journal of the American College of Cardiology Percutaneous Coronary InterventionEndovascular TechniqueCardiovascular DiseaseMedicineVascular Surgery	2013	220
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial Seung‐Jung Park, Jung‐Min Ahn, Do‐Yoon Kang, The Lancet Percutaneous Coronary InterventionOptimal Medical TherapyCardiovascular DiseaseHealth PolicyPreventive Cardiology	2024	212
Prognostic Implications of Door‐to‐Balloon Time and Onset‐to‐Door Time on Mortality in Patients With ST‐Segment–Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Jonghanne Park, Ki Hong Choi, Joo Myung Lee, Journal of the American Heart Association Further ShorteningTimely Reperfusion TherapyPrognostic ImplicationsCoronary Artery DiseaseAcute Myocardial Infarction	2019	205
Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures Ki Hong Choi, Young Bin Song, Joo Myung Lee, JACC: Cardiovascular Interventions Percutaneous Coronary InterventionMedical UltrasoundEndovascular TechniqueCardiovascular DiseaseAtherosclerosis	2019	173

Page 1